Astellas Starts Phase 3 Study of Setidegrasib in Lung Cancer
Tokyo, Japan, September 24, 2026 Astellas Pharma Inc. has dosed the first patient in a Phase 3 clinical study...
Cancer Screening
Advertisement
GRAIL Galleri Wins FDA Panel Support for Cancer Test
Sunnyvale, California, September 23, 2026 GRAIL, Inc. announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics...
Caris Life Sciences Promotes Caris Detect for Cancer
Irving, Texas, U.S, September 8, 2026 Caris Life Sciences, an artificial intelligence and precision medicine company, has launched a...
Guardant Health Expands Shield CRC Screening Coverage
PALO ALTO, Calif., Sept. 1, 2026 Guardant Health announced that its Shield blood test for colorectal cancer (CRC) screening...
Guardant Health Launches Patrick Dempsey Campaign for CRC Screening
PALO ALTO, Calif., July 28, 2026 Guardant Health, Inc. has launched a new colorectal cancer (CRC) awareness campaign featuring...
Advertisements
GRAIL Teams with Priority Health to Expand Galleri
MENLO PARK, Calif., July 16, 2026 GRAIL, Inc. has announced a strategic collaboration with Priority Health, making the Galleri®...
Freenome Reports Strong SimpleScreen CRC Study Results
BRISBANE, Calif. | July 9, 2026 Freenome, an early cancer detection company advancing blood-based cancer screening technologies, has announced...
Johnson & Johnson’s RYBREVANT FASPRO Shows Strong HNSCC Results
CHICAGO, Illinois, May 31, 2026 Johnson & Johnson has reported pivotal results from the Phase 1b/2 OrigAMI-4 study, demonstrating...
GRAIL’s Galleri® Test Increases Cancer Detection 6.5-Fold in PATHFINDER 2 Study
MENLO PARK, California, May 31, 2026 GRAIL, Inc. has unveiled compelling new results from its registrational PATHFINDER 2 study,...
Gene Solutions Wins FDA Breakthrough Status for SPOT-MAS 10
SINGAPORE, May 28, 2026 Gene Solutions announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device...
Advertisement
